News | October 16, 2024
Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
We now rank 3rd in pharmaceutical production by volume and 14th by value
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
This is used to treat central diabetes insipidus and bedwetting
Subscribe To Our Newsletter & Stay Updated
